Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma

Experimental and Molecular Pathology

Volumn 99, Issue 3, 2015, Pages 485-491

  Melchior, Linea ^a   Grauslund, Morten ^a   Bellosillo, Beatriz ^b   Montagut, Clara ^b   Torres, Erica ^b   Moragón, Ester ^b   Micalessi, Isabel ^c   Frans, Johan ^c   Noten, Veerle ^c   Bourgain, Claire ^c   Vriesema, Renske ^d   van der Geize, Robert ^d   Cokelaere, Kristof ^e   Vercooren, Nancy ^e   Crul, Katrien ^e   Rüdiger, Thomas ^f   Buchmüller, Diana ^f   Reijans, Martin ^g   Jans, Caroline ^g  

^a Mental Health Services CPH   (Denmark)

^b HOSPITAL DEL MAR   (Spain)

^c IMELDA HOSPITAL   (Belgium)

^d Laboratorium Pathologie Oost Nederland   (Netherlands)

^e Jan Yperman Hospital   (Belgium)

^f STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^g Biocartis SA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; BRAF PROTEIN, HUMAN; FORMALDEHYDE; PARAFFIN;

ARTICLE; BRAF GENE; CONTROLLED STUDY; FORMALIN FIXED PARAFFIN EMBEDDED TISSUE; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MELANOMA; MICRODISSECTION; MULTICENTER STUDY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION SYSTEM; QUALITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SANGER SEQUENCING; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; TISSUE SECTION; TURNAROUND TIME; CLINICAL TRIAL; EVALUATION STUDY; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS;

DNA MUTATIONAL ANALYSIS; FORMALDEHYDE; HUMANS; MELANOMA; MUTATION; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; SKIN NEOPLASMS;

EID: 84942940354     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.09.004     Document Type: Article

References (22)

1. Chong H., Vikis H.G., Guan K.L. Mechanisms of regulating the Raf kinase family. Cell. Signal. 2003, 15:463-469.
2. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
3. Hall R.D., Kudchadkar R.R. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Cancer Control 2014, 21:221-230.
4. Menzies A.M., Haydu L.E., Visintin L., Carlino M.S., Howle J.R., Thompson J.F., Kefford R.F., Scolyer R.A., Long G.V. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 2012, 18:3242-3249.
5. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49:1374-1403.
6. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65:5-29.
7. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., Buzaid A.C., Cochran A.J., Coit D.G., Ding S., Eggermont A.M., Flaherty K.T., Gimotty P.A., Kirkwood J.M., McMasters K.M., Mihm M.C., Morton D.L., Ross M.I., Sober A.J. Sondak VK: final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009, 27:6199-6206.
8. Spagnolo F., Ghiorzo P., Orgiano L., Pastorino L., Picasso V., Tornari E., Ottaviano V., Queirolo P. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco. Targets Ther. 2015, 8:157-168.
9. Klein O., Clements A., Menzies A.M., O'Toole S., Kefford R.F., Long G.V. BRAF inhibitor activity in V600R metastatic melanoma. Eur. J. Cancer 2013, 49:1073-1079.
10. Parakh S., Murphy C., Lau D., Cebon J.S., Andrews M.C. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. J. Clin. Pharm. Ther. 2015, 40:121-123.
11. Ponti G., Pellacani G., Tomasi A., Gelsomino F., Spallanzani A., Depenni R., Al Jalbout S., Simi L., Garagnani L., Borsari S., Conti A., Ruini C., Fontana A., Luppi G. The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. J. Clin. Pathol. 2013, 66:441-445.
12. Colomba E., Hélias-Rodzewicz Z., Von Deimling A., Marin C., Terrones N., Pechaud D., Surel S., Côté J.F., Peschaud F., Capper D., Blons H., Zimmermann U., Clerici T., Saiag P., Emile J.F. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J. Mol. Diagn. 2013, 15:94-100.
13. Ihle M.A., Fassunke J., König K., Grünewald I., Schlaak M., Kreuzberg N., Tietze L., Schildhaus H.U., Büttner R., Merkelbach-bruse S. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer 2014, 14:13.
14. Janku F., Claes B., Huang H.H., Falchook G.S., Devogelaere B., Kockx M., Vanden Bempt I., Reijans M., Naing A., Fu S., Piha-Paul S.A., Hong D.S., Holley V.R., Tsimberidou A.M., Stepanek V.M., Patel S.P., Kopetz E.S., Subbiah V., Wheler J.J., Zinner R.G., Karp D.D., Luthra R., Roy-Chowdhuri S., Sablon E., Meric-Bernstam F., Maertens G., Kurzrock R. BRAF mutation testing with a rapid and fully integrated molecular diagnostics system. Clin. Chem. 2015, (in press).
15. Schiefer A., Parlow L., Gabler L., Koperek O., von Deimling A., Streubel B., Preusser M., Dietel M., Hummel M., Klauschen F., Birner P., Möbs M. Multicenter evaluation of a novel, automated PCR-based system for rapid detection of BRAF status in formalin-fixed, paraffin embedded tissues. Mod. Pathol. 2015, (in press).
16. van Eijk R., Licht J., Schrumpf M., Talebian Yazdi M., Ruano D., Forte G.I., Nederlof P.M., Veselic M., Rabe K.F., Annema J.T., Smit V., Morreau H., van Wezel T. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One 2011, 6.
17. Anderson S., Bloom K.J., Vallera D.U., Rueschoff J., Meldrum C., Schilling R., Kovach B., Lee J.R., Ochoa P., Langland R., Halait H., Lawrence H.J., Dugan M.C. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch. Pathol. Lab. Med. 2012, 136:1385-1391.
18. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T., McArthur G.A. BRIM-3 Study Group: improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516.
19. McArthur G.A., Chapman P.B., Robert C., Larkin J., Haanen J.B., Dummer R., Ribas A., Hogg D., Hamid O., Ascierto P.A., Garbe C., Testori A., Maio M., Lorigan P., Lebbé C., Jouary T., Schadendorf D., O'Day S.J., Kirkwood J.M., Eggermont A.M., Dréno B., Sosman J.A., Flaherty K.T., Yin M., Caro I., Cheng S., Trunzer K., Hauschild A. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014, 15:323-332.
20. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., Hamid O., Infante J.R., Millward M., Pavlick A.C., O'Day S.J., Blackman S.C., Curtis C.M., Lebowitz P., Ma B., Ouellet D., Kefford R.F. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
21. Yang H., Higgins B., Kolinsky K., Packman K., Go Z., Iyer R., Kolis S., Zhao S., Lee R., Grippo J.F., Schostack K., Simcox M.E., Heimbrook D., Bollag G., Su F. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010, 70:5518-5527.
22. Ponti G., Tomasi A., Pellacani G. Overwhelming response to dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma. J. Hematol. Oncol. 2012, 5:60.